Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment

Detalles Bibliográficos
Autores principales: Betrian, S, Ysebaert, L, Heider, K H, Delord, J P, Fournié, J J, Quillet-Mary, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148053/
https://www.ncbi.nlm.nih.gov/pubmed/27834943
http://dx.doi.org/10.1038/bcj.2016.106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148053/
https://www.ncbi.nlm.nih.gov/pubmed/27834943
http://dx.doi.org/10.1038/bcj.2016.106

Ejemplares similares